Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The primary objective of the trial is to determine the maximum tolerated doses (MTD) of BI 860585 alone and in combination with exemestane or paclitaxel. To determine the MTDs, patients are entered sequentially into escalating dose cohorts. Secondary objectives are objective response and disease control according to RECIST criteria version 1.1
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Additional inclusion criteria for the combination arms:
Additional inclusion criteria for expansion part:
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
90 participants in 3 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal